FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APF	OMB APPROVAL						
OMB Number: 3235-0							
Estimated average burden							
hours per response	: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SUTTER HILL VENTURES</u>			2. Date of Event Requiring Statement (Month/Day/Year) 04/14/2004 3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]								
(Last) (First) (Middle) 755 PAGE MILL ROAD, SUITE A-200				Relationship of Reporting Perso (Check all applicable) Director X	()	(Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)				
(Street) PALO ALTO CA 943041005 (City) (State) (Zip)				Officer (give title below)	Other (spe- below)	cify 6. Ir	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	t (D) (Insti	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)		str. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiratior Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)			
Series A Prefer	rred Stock		(1)	(2)	Common Stock	791,586	0.0000(3)	D			
Series B Prefer	rred Stock		(1)	(2)	Common Stock	569,940	0.0000(3)	D			
Series BB Pref	erred Stock		(1)	(2)	Common Stock	121,780	0.0000(4)	D			
Series C Prefer	rred Stock		(1)	(2)	Common Stock	732,882	0.0000(4)	D			

Explanation of Responses:

- 1. Immediately.
- 2. Not applicable.
- 3. Each preferred share is convertible without consideration into three (3) shares of common stock.
- ${\bf 4.} \ Each \ preferred \ share \ is \ convertible \ without \ consideration \ into \ one \ (1) \ share \ of \ common \ stock.$

Remarks:

By: Robert Yin, by power of <u>attorney</u>

04/14/2004

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby authorizes David E. Sweet, Robert Yin, or Patricia Tom to execute for and on behalf of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Incorporated ("the Company"), and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneyin-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such a capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

In witness whereof, the undersigned has caused this Power of Attorney to be executed as of this 13th day of April, 2004.

SUTTER HILL VENTURES, A CALIFORNIA LIMITED PARTNERSHIP

/s/ William H. Younger, Jr.
Managing Director of the General Partner